Merck & Company Inc (MRK)vsVerrica Pharmaceuticals Inc (VRCA)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
VRCA
Verrica Pharmaceuticals Inc
$6.04
-1.79%
HEALTHCARE · Cap: $103.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 176881% more annual revenue ($65.77B vs $37.16M). MRK leads profitability with a 13.6% profit margin vs -48.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
VRCA
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+78.1%
Fair Value
$25.37
Current Price
$6.04
$19.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 46.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -111.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : VRCA
The strongest argument for VRCA centers on Revenue Growth, Debt/Equity. Revenue growth of 46.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : VRCA
The primary concerns for VRCA are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while VRCA is a hypergrowth play — different risk/reward profiles.
VRCA carries more volatility with a beta of 1.49 — expect wider price swings.
VRCA is growing revenue faster at 46.1% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 27/100). VRCA offers better value entry with a 78.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Verrica Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Verrica Pharmaceuticals Inc., a dermatological therapy company, develops and markets treatments for people with skin conditions in the United States. The company is headquartered in West Chester, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?